Chronic Renal Failure Clinical Trial
— DEScoverOfficial title:
Prospective, Randomized, Controlled, Multicenter Study of the Solaris DE Endoprosthesis in the Treatment of Venous Outflow Stenosis or Occlusion in Hemodialysis Patients
The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris DE Endoprosthesis in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including arteriovenous (AV) fistula and synthetic AV graft. Participants will be treated with Solaris DE Endoprosthesis. Researchers will compare the treatment with investigational product to Percutaneous Transluminal Angioplasty (PTA) alone within the AV fistula cohort in order to demonstrate superiority of Solaris DE.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | September 2027 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - The participant has a mature AV Fistula (AVF) or Graft (AVG) in the arm created = 30 days before the initial procedure and is in use for dialysis therapy - The participant has clinical and/or hemodynamic evidence of a venous outflow obstruction or AV fistula or graft dysfunction. The stenotic lesion is = 50%, with a maximum length of 8 cm and a vessel diameter from 4.0 mm to 9.0 mm - The participan provides written informed consent prior to any study-specific procedure - The participan is willing to undergo all follow-up evaluations according to the specified schedule over 24 months Angiographic Inclusion Criteria: - The target lesion originates = 3 cm from the cannulation segment (needling zone) - The target lesion is located: 1. In one arm (including the cephalic arch) in a participant with AVF, and not in the cannulation segment, OR 2. In the anastomosis or juxta-anastomosis in a participant with AVF (a juxta-anastomosis is defined as a location where the stent crosses the venous anastomosis) - The target lesion includes a de novo stenotic lesion or restenosis - The target lesion is = 5 cm from the arterial anastomosis - The target lesion has = 50% stenosis according to the operator's visual judgment - The reference vessel diameter of the target lesion is between 4.0 mm and 9.0 mm by the operator's visual judgment - Single or multiple target lesions measuring = 8 cm in total length by the operator's visual judgment - Single or multiple target lesions should be covered by a single stent or multiple overlapping stents, provided they are treated as a single lesion with a maximum length of 8 cm - Successful target lesion pre-dilatation is defined as crossover of the guidewir resulting in full expansion of the pre-dilatation balloon - The participant has up to 1 (one) non-target lesion in the venous outflow circuit requiring intervention in the initial procedure. The non-target lesion must be at least 10 cm away from the target lesion. The non-target lesion can only be treated with standard PTA alone - Does not have stent implanted or it has been in the access circuit for = 30 days since placement and patent with = 30% stenosis and located = 5 cm from the target lesion - The non-target lesion must be successfully treated at the time of the initial procedure (success measured as =30% residual stenosis and no complications). Exclusion Criteria: - Pregnant, breastfeeding or with intention to become pregnant in the next year - The participant has any major endovascular or surgical procedure planned (including in the access circuit) within 30 days of the initial procedure - It was not possible to pre-dilate the lesion to be treated with Solaris DE - Planned surgical revision of the access site - Known or suspected infection of the hemodialysis access site, systemic infection and/or sepsis - Patients on immunosuppressive therapy - Known active coagulopathy or bleeding diathesis - Known hypersensitivity to nickel titanium alloy, contrast or sirolimus - Contraindication to antiplatelet, anticoagulant or thrombolytic therapies - Known allergy to contrast agents or medications administered to perform endovascular intervention that cannot be adequately premedicated - Life expectancy of less than 12 months - Has a stent or endoprosthesis located anywhere in the AV access circuit that is not patent (> 30% stenosis) or implanted < 30 days - The participant's hemodialysis access is expected to be abandoned within 6 months - The participantis is enrolled in another trial involving an investigational product (pharmaceutical, biological or medical device) Angiographic Exclusion Criteria: - The target lesion is located inside an endoprosthesis - Target lesion treatment would involve the cannulation segment (needling zone) - The target lesion is < 5 cm from the arterial anastomosis - Evidence of an aneurysm, pseudoaneurysm or acute thrombus (i.e. one that has been treated = 15 days) within the target lesion - The target lesion is, and/or Solaris DE would be placed anywhere: 1. Through the elbow 2. In the cannulation segment (needling zone) 3. Inside any part of a pre-existing stent or endoprosthesis (apart from an access arteriovenous graft) 4. Lower extremity 5. Non-synthetic graft - The target lesion is located in such a way that the insertion of a stent would result in a "kink" area that requires a stent bridge between the Solaris DE and an existing stent or stent graft - The individual has more than 1 (one) non-target lesion (= 50% stenosis) that requires intervention in the initial procedure |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Scitech Produtos Medicos Ltda |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Events | Percentage of participants without any safety events affecting the access or venous outflow circuit and resulting in new intervention, hospitalization or death (not including stenosis or thrombosis). | 30 days | |
Primary | Target Lesion Primary Patency (TLPP) | Percentage of participants without restenosis or clinically indicated target lesion revascularization or thrombosis. | 6 months | |
Secondary | Target Lesion Primary Patency (TLPP) | Percentage of participants without restenosis or clinically indicated target lesion revascularization or thrombosis. | 12 and 24 months | |
Secondary | Assisted Target Lesion Primary Patency (aTLPP) | Percentage of participants without uncorrectable occlusion of the target lesion since the procedure. | 1, 6, 12 and 24 months | |
Secondary | Access Circuit Primary Patency (ACPP) | Percentage of participants without any new venous outflow circuit intervention, thrombosis or access abandonment since the procedure. | 1, 6, 12 and 24 months | |
Secondary | Cumulative Patency (CP) | Percentage of participants without the access circuit abandonment since the procedure. | 1, 6, 12 and 24 months | |
Secondary | Procedure and device-related complications | Complication rates related to the procedure and device involving the access circuit. | 1, 6, 12 and 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02565459 -
MSC and Kidney Transplant Tolerance (Phase A)
|
Phase 1 | |
Recruiting |
NCT02356419 -
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
|
Phase 1 | |
Recruiting |
NCT01876017 -
Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03019159 -
Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis
|
N/A | |
Completed |
NCT02047006 -
Dose-finding of Rivaroxaban in Hemodialysis
|
Phase 4 | |
Completed |
NCT01617824 -
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00597753 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 | |
Completed |
NCT00828776 -
Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT00372489 -
Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD
|
Phase 2 | |
Completed |
NCT00379899 -
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
|
Phase 4 | |
Completed |
NCT00228436 -
Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients
|
Phase 2 | |
Completed |
NCT03772171 -
Estimate for Dietary Intakes and Hemodialysis Patients
|
||
Recruiting |
NCT02586402 -
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
|
Phase 2 | |
Completed |
NCT01879618 -
Use Of Fragmin In Hemodialysis
|
Phase 3 | |
Not yet recruiting |
NCT01346215 -
Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure
|
Phase 3 | |
Completed |
NCT01220843 -
FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease
|
Phase 3 | |
Completed |
NCT01111630 -
Study of Erythropoietin (EPO) Administration Schedule
|
Phase 4 | |
Completed |
NCT00742716 -
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT00598273 -
Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
|
Phase 3 | |
Completed |
NCT00597584 -
Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis
|
Phase 3 |